ANIX — Anixa Biosciences Income Statement
0.000.00%
Last trade - 00:00- $91.79m
- $75.41m
- 22
- 13
- 79
- 31
Annual income statement for Anixa Biosciences, fiscal year end - October 31st, USD millions except per share, conversion factor applied.
2021 October 31st | 2022 October 31st | 2023 October 31st | 2024 October 31st | 2025 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.512 | 0 | 0.21 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 13.6 | 13.9 | 11.2 | 13.8 | 11.7 |
| Operating Profit | -13.1 | -13.9 | -11 | -13.8 | -11.7 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -13.1 | -13.8 | -9.93 | -12.7 | -11 |
| Net Income After Taxes | -13.1 | -13.8 | -9.93 | -12.7 | -11 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -13 | -13.6 | -9.81 | -12.6 | -10.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13 | -13.6 | -9.81 | -12.6 | -10.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.44 | -0.448 | -0.311 | -0.394 | -0.337 |